Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy

European Journal of Ophthalmology

Volumn 21, Issue 3, 2011, Pages 243-250

  Monaco, Gaspare ^a   Cacioppo, Viviana ^a   Consonni, Dario ^a   Troiano, Pasquale ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Compatible solute; Confocal microscopy; Glaucoma; Ocular surface; Optive osmoprotection

Indexed keywords

ARTIFICIAL TEAR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOXYMETHYLCELLULOSE; DYE; GLYCEROL; HYALURONIC ACID; ISOTONIC SOLUTION; OPTIVE; PROSTAGLANDIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORNEA THICKNESS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EYE INJURY; EYE PROTECTION; GLAUCOMA; HUMAN; IN VIVO STUDY; INTRAOCULAR PRESSURE; OSMOSIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TEAR FILM;

ADRENERGIC BETA-ANTAGONISTS; CARBOXYMETHYLCELLULOSE SODIUM; CORNEA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRY EYE SYNDROMES; GLAUCOMA, OPEN-ANGLE; GLYCEROL; HUMANS; HYALURONIC ACID; INTRAOCULAR PRESSURE; ISOTONIC SOLUTIONS; MICROSCOPY, CONFOCAL; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; PROSTAGLANDINS, SYNTHETIC; TEARS;

EID: 79953658912     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2010.5730     Document Type: Article

References (63)

1. 2007 Report of the International Dry Eye WorkShop (DEWS). Ocul Surf 2007; 5: 13-22.
2. Weissman SS, Asbell PA. Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity. Br J Ophthalmol 1990; 74: 409-412.
3. Niiya A, Yokoi N, Matsumoto Y, et al. Effect of beta-blocker eyedrops on corneal epithelial barrier function. Ophthalmo-logica 2000; 214: 332-336.
4. de Jong C, Stolwijk T, Kuppens E, de Keizer R, van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofuorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol 1994; 232: 221-224.
5. Bonomi L, Zavarise G, Noya E, Michieletto S. Effects of timolol on tear fow in human eyes. Graefes Arch Klin Exp Ophthalmol 1980; 213: 19-22.
6. Kuppens EV, de Jong CA, Stolwijk TR, de Keizer RJ, van Best JA. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol 1995; 79: 39-342.
7. Shimazaki J, Hanada K, Yagi Y, et al. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol vs 0.12% unoprostone. Br J Ophthalmol 2000; 84: 1250-1254.
8. Strempel I. The infuence of topical β-blockers on the break up time. Ophthalmologica 1984; 189: 110-115.
9. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglau-comatous drug. Ophthalmology 1992; 99: 1082-1088.
10. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology 1989; 96: 327-335.
11. Mackie IA, Seal DV, Pescod JM. Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction. Br J Ophthalmol 1977; 61: 354-359.
12. Higginbotham EJ, Schuman JS, Goldberg I, et al, Bimato-prost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120: 1286-1293.
13. Netland PA, Landry T, Sullivan EK, et al, Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-484.
14. Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eye-drops and nocturnal arterial hypotension. Am J Ophthalmol 1999; 128: 301-309.
15. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997; 41(suppl 2): S105-S110.
16. Sherwood M, Brandt J, Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2000; 45(suppl 4): S361-S368.
17. Brubaker R F, Schoff EO, Nau CB, Carpenter S P, Chen K, Vandenburgh AM. Effects of AGN 192024, a new ocular hy-potensive agent, on aqueous dynamics. Am J Ophthalmol 2001; 131: 19-24.
18. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM, Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Oph-thalmol 2003; 135: 55-63.
19. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997; 115: 1206-1208.
20. Sudesh S, Cohen EJ, Rapuano CJ, Wilson R P. Corneal tox-icity associated with latanoprost. Arch Ophthalmol 1999; 117: 539-540.
21. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999; 127: 602-604.
22. Warwar RE, Bullock JD. Latanoprost-induced uveitis. Surv Ophthalmol 1999; 43: 466-468.
23. Gasset AR, Ishii Y, Kaufman H, Miller T. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 1974; 78: 98-105.
24. Wilson FM. Adverse external effects of topical ophthalmic medications. Surv Ophthalmol 1979; 24: 57-88.
25. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol 1980; 25: 15-30.
26. Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Oph-thalmol Soc UK 1985; 104: 402-409.
27. Brubaker R F, McLaren J. Uses of the fuorophotometer in glaucoma research. Ophthalmology 1985; 92: 884-890.
28. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artifcial tear preparations: assessment of corneal epithelial toxic effects. Arch Ophthalmol 1992; 110: 528-532.
29. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathol-ogy of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994; 232: 561-565.
30. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of infammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994; 101: 454-460.
31. Lavin MJ, Wormald R P, Migdal CS, Hitchings RA. The in-fuence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990; 108: 1543-1548.
32. Longstaff S, Wormald R P, Mazover A, Hitchings RA. Glaucoma triple procedures: efficacy of intraocular pressure control and visual outcome. Ophthalmic Surg 1990; 21: 786-793.
33. Miller MH, Rice NS. Trabeculectomy combined with irradiation for congenital glaucoma. Br J Ophthalmol 1991; 75: 584-590.
34. Broadway D, Grierson I, Hitchings R. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol 1993; 77: 590-596.
35. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjuncti-val cell profle. Arch Ophthalmol 1994; 112: 1437-1445.
36. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996; 7: 80-86.
37. Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye: I: basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1593-1601.
38. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd ed. Savona: Dogma, 2008; 1-183.
39. Masschelein WJ, Rice RG. In: Chlorine Dioxide: Chemistry and Environmental Impact of Oxychlorine Compounds. Ann Arbor, MI: Ann Arbor Science Publishers, 1979 1-190.
40. Horio M, Ito A, Matsuoka Y, et al. Apoptosis induced by hy-pertonicity in Madin Darley canine kidney cells: protective effect of betaine. Nephrol Dial Transplant 2001; 16: 483-490.
41. Alferi RR, Cavazzoni A, Petronini PG, et al. Compatible os-molytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis. J Physiol 2002; 540: 499-508.
42. deZengotita VM, Abston LR, Schmelzer AE, Shaw S, Miller WM. Selected amino acids protect hybridoma and CHO cells from elevated carbon dioxide and osmolality. Biotech-nol Bioeng 2002; 78: 741-752.
43. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000; 118: 615-621.
44. Stonecipher KG, Green PT. Non-contact confocal microscopy of the tear film in unoperated eyes. J Refract Surg 2007; 23: 417-419.
45. Bron AJ, Evans VE, Smith JA. Grading of corneal and con-junctival staining in the context of other dry eye tests. Cornea 2003; 22: 640-650.
46. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research, 4th ed. Oxford: Blackwell Science; 2002: 627-634.
47. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86: 418-423.
48. Karadayi K, Ciftci F, Akin T, Bilge AH. Increase in central corneal thickness in dry and normal eyes with application of artifcial tears: a new diagnostic and follow-up criterion for dry eye. Ophthalmic Physiol Opt 2005; 25: 485-491.
49. Liu Z, Pfugfelder SC. Corneal thickness is reduced in dry eye. Cornea 1999; 18: 403-407.
50. van Bijsterveld O P, Baardman J. Measurements of corneal thickness in patients with keratoconjunctivitis sicca. Klin Monatsbl Augenheilkd 1990; 197: 240-243.
51. Pole JJ, Batzer JK. Central corneal thickness of patients with dry eyes. J Am Optom Assoc 1985; 56: 220-221.
52. Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci 2006; 47: 4309-4315.
53. Gilles R. "Compensatory" organic osmolytes in high os-molarity and dehydration stresses: history and perspective. Comp Biochem Physiol Physiol 1997; 117: 279-290.
54. Yancey PH. Organic osmolytes as compatible, metabolic and counteracting cryoprotectants in high osmolarity and other stresses. J Exp Biol 2005; 208: 2819-2830.
55. Mager WH, Siderius M. Novel insights into the osmotic stress response of yeast. FEMS Yeast Res 2002; 2: 251-257.
56. Corrales RM, Luo L, Chang EY, Pfugfelder SC. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea 2008; 27: 574-579.
57. Paugh JR, Nguyen AL, Ketelson HA, Christensen MT, Meadows DL. Precorneal residence time of artifcial tears measured in dry eye subjects. Optom Vis Sci 2008; 85: 725-731.
58. Mochizuki H, Yamada M, Hatou S, Tsubota K. Turnover rate of tear-film lipid layer determined by fuorophotom-etry. Br J Ophthalmol 2009; 93: 1535-1538.
59. Grene RB, Lankston P, Mordaunt J, Harrold M, Gwon A, Jones R. Unpreserved carboxymethylcellulose artifcial tears evaluated in patients with keratoconjunctivitis sicca. Cornea 1992; 11: 294-301.
60. Donshik PC, Nelson JD, Abelson M. Effectiveness of HPMC, CMC, Aquasite, and Refresh Plus for moderate to severe dry eye. Adv Exp Med Biol 1998; 438: 753-760.
61. Garrett Q, Simmons PA, Xu S, et al. Carboxymethylcellu-lose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthal-mol Vis Sci 2007; 48: 1559-1567.
62. Tiffany JM. Viscoelastic properties of human tears and plìolymer solutions. Adv Exp Med Biol 1994; 350: 267-270.
63. Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superfcial keratitis. Graefes Arch Clin Exp Ophthalmol 2005; 243: 531-538.